HomeAbiomed

Abiomed

Impella RP Post-Approval Study Data Presented at ACC 2019

3/18/19: The Impella RP is the only percutaneous technology with FDA PMA approval for right heart support designated safe and effective. The table below summarizes the new post-approval study data and compares it to the FDA study results submitted for Impella RP’s PMA approval.

Abiomed Invests $100 Million Plus Over the Past Five Years in Clinical Research on the Impella Heart Pump Platform

2/25/19: Abiomed launched a new webpage today that shows their commitment to clinical research regarding the Impella Heart Pump Platform.

Abiomed: FDA Safety Study of Unloading the Left Ventricle for 30 Minutes Prior to Reperfusion in Heart Attack Patients is Safe and Feasible

11/12/18: FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, which show unloading the left ventricle with Impella CP® for 30 minutes prior to reperfusion in patients presenting with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock is safe and feasible, when compared to Impella patients reperfused immediately.